Resource Constraints Preventing FDA From Getting Full Benefits of QbR
This article was originally published in The Gold Sheet
Generic drug reviews falling behind despite new question-based-review approach due to increasing workload and declining resources, including a lack of user fees. How to improve QbR and microbiology submissions and reduce first-cycle review times. How more frequently updated dissolution and inactive ingredient databases could help.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
Action responds to methanol contamination in hand sanitizers manufactured in Mexico and marketed in the US under numerous brands that followed a loosening standards for the products to drive a swift increase in production and meet surging demand during the coronavirus pandemic.
New import alert category and border testing required after reduced standards put dangerous sanitizers into hands of US consumers.